Atypical pharmacokinetics of atazanavir in an HIV‐1‐infected patient

An HIV‐infected patient with very low atazanavir (ATV) plasma trough concentrations despite clinical signs of poor drug tolerability was described. By therapeutic drug monitoring (TDM), the authors found that the patient had an atypical ATV pharmacokinetics characterized by rapid drug absorption fol...

Full description

Saved in:
Bibliographic Details
Published in:Fundamental & clinical pharmacology 2012-04, Vol.26 (2), p.204-206
Main Authors: Cattaneo, Dario, Meraviglia, Paola, Cozzi, Valeria, Baldelli, Sara, Milani, Greta, Clementi, Emilio
Format: Article
Language:English
Subjects:
Anti-HIV Agents - adverse effects
Anti-HIV Agents - pharmacokinetics
Anti-HIV Agents - therapeutic use
Atazanavir Sulfate
Biological and medical sciences
Drug Monitoring
HAART
HIV
HIV Infections - drug therapy
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Male
Medical sciences
Middle Aged
Oligopeptides - adverse effects
Oligopeptides - pharmacokinetics
Oligopeptides - therapeutic use
Pharmacogenetics
pharmacokinetics
Pharmacology. Drug treatments
Pyridines - adverse effects
Pyridines - pharmacokinetics
Pyridines - therapeutic use
therapeutic drug monitoring
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An HIV‐infected patient with very low atazanavir (ATV) plasma trough concentrations despite clinical signs of poor drug tolerability was described. By therapeutic drug monitoring (TDM), the authors found that the patient had an atypical ATV pharmacokinetics characterized by rapid drug absorption followed by very fast drug clearance probably attributable to his genetic background. This case underlines the importance of traditional and pharmacogenetic‐based TDM for the individualization of ATV therapy in HIV‐1 patients.
ISSN:0767-3981
1472-8206
DOI:10.1111/j.1472-8206.2010.00905.x